LaserGen | GenomeWeb

LaserGen

The firm's $80 investment in Lasergen sets the stage for it to develop an integrated sample-to-result clinical genomics workflow by 2020.

Agilent said it will work with Lasergen to build a clinical sequencing workflow based on the smaller firm's Lightning Terminators sequencing chemistry.

LaserGen has named Mimi Healy CEO and to its board of directors. She is taking over from founder Michael Metzker, who developed and patented the company's proprietary Lightning Terminators.

By Julia Karow
This article has been updated to include information about Roche/IBM and Genia.

LaserGen has raised $5 million in a Series A financing round, which it will use to demonstrate accurate sequencing of the Escherichia coli genome and to continue developing its next-generation sequencing system.

Last week, the Baylor College of Medicine spinout disclosed that it has teamed up with National Instruments to build and validate a prototype sequencer that uses its "Lightning Terminator" chemistry.

The firms aim to have a system developed and installed at a genome center for validation testing by the end of this year.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.